Opendata, web and dolomites

RAPID

RNA particles for Preparedness against Infectious Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RAPID" data sheet

The following table provides information about the project.

Coordinator
BUNYAVAX BV 

Organization address
address: GOLFPARK 115
city: LELYSTAD
postcode: 8241 AC
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.bunyavax.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BUNYAVAX BV NL (LELYSTAD) coordinator 50˙000.00

Map

 Project objective

BunyaVax builds unprecedented technology for cost-effective and rapid development of vaccines against newly emerging viruses. The platform can be a valuable tool in quickly controlling the spread of new virus strains among populations. The timing of RAPID closely corresponds with a current focus of the vaccine industry on novel vaccine platform technologies that enable rapid response to emerging threats.

The BunyaVax RNA particle technology combines the efficacy of live vaccines with the safety of inactivated or subunit vaccines – which are currently the standard vaccine technologies. A unique characteristic of the RNA platform is that it allows for ‘plug and play’ application. Any gene can be plugged into the RNA particle genome to generate inherently safe and efficacious vaccines. The platform can stably express a broad variety of pathogen derived antigens. A major advantage is that development and manufacturing can be completed in a timeframe of 16 weeks which is at least twice as fast as current methods. The BunyaVax technology is in a stage of proven efficacy in sheep.

RAPID is designed to prepare for partnerships with vaccine manufacturers and/or venture capital firms and to lay the foundation for clinical application of the vaccine platform. Key steps for upscaled production levels will be taken.

The innovation project is at the core of the strategy of BunyaVax. The project is instrumental for reaching a stage in which commercial partnerships can be explored. Ultimately, this will allow BunyaVax to forward the technology to a stage in which industry can use it to develop vaccines for controlling veterinary and human infectious disease outbreaks at an earlier stage than currently possible.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More